Search for: "Hospira"
Results 81 - 100
of 487
Sort by Relevance
|
Sort by Date
30 Oct 2017, 9:05 pm
Hospira, Inc. v. [read post]
18 Aug 2017, 2:15 am
Hospira, Inc., (Fed. [read post]
18 Aug 2017, 2:15 am
Hospira, Inc., (Fed. [read post]
16 Aug 2017, 8:21 am
Hospira (Fed. [read post]
11 Aug 2017, 9:09 am
By John C. [read post]
11 Aug 2017, 6:06 am
Hospira,Inc., No. 16-2179 (Fed. [read post]
10 Aug 2017, 9:58 pm
Hospira, Inc. answered a question that had been lingering since the very first case -- can a reference product sponsor use discovery to obtain information from a biosimilar applicant if it does not receive a copy of the aBLA or other information about the manufacturing process as required by the BPCIA? [read post]
26 Jun 2017, 11:27 am
Over concerns of sterility, Hospira Inc., a Pfizer company, has voluntarily recalled three injectable products, as of June 15, 2017. [read post]
19 Jun 2017, 7:03 am
” Bloomberg says “Pfizer acquired the plant with its about $17 billion takeover of Hospira in 2015. [read post]
13 Jun 2017, 12:00 pm
Hospira, Inc., that Metallizing Engineering may remain good law under the AIA. [read post]
13 Jun 2017, 12:00 pm
Hospira, Inc., that Metallizing Engineering may remain good law under the AIA. [read post]
8 Jun 2017, 3:27 am
Hospira, Inc., that Metallizing Engineering may remain good law under the AIA. [read post]
6 Jun 2017, 9:04 pm
By Andrew Williams -- On May 25, 2017, the FDA's Oncologic Drug Advisory Committee recommended approval of biologics license application ("BLA") 125545 submitted by Hospira Inc., a Pfizer company, for Retacrit, a proposed biosimilar to Amgen Inc.'s Epogen/Procrit (epoetin alfa). [read post]
1 May 2017, 10:58 am
Hospira, Inc., 827 F.3d 1363 (Fed. [read post]
7 Apr 2017, 12:54 pm
Additionally, Hospira found that a drug pump it manufactured could potentially be hacked as well. [read post]
6 Apr 2017, 1:35 pm
Hospira,Inc., 791 F.3d 1368, 1372 (Fed. [read post]
25 Jan 2017, 10:48 pm
”However, in Hospira v Cubist [2016] EWHC 1285 (Pat), Carr J suggested that he would have found Claim 1, which included the use of a standard buffer, a standard agent and a standard purification process, obvious over the CGK alone had he not already found it obvious over a piece of prior art. [read post]
29 Dec 2016, 12:36 pm
Defendant is Hospira, Inc. of Lake Forest, Illinois. [read post]
12 Dec 2016, 7:15 am
Brian CorderyBristowsby Chloe Dickson On 30 November 2016 the Court of Appeal handed down judgment in the latest chapter of the Hospira v Genentech epic surrounding Genentech’s blockbuster drug trastuzumab (Herceptin®) (Hospira v Genentech [2016] EWCA Civ 1185). [read post]
7 Dec 2016, 1:03 pm
In District Court, Hospira alleged that the patents were invalid because the on-sale bar was triggered when MedCo paid Ben Venue to manufacture Angiomax before the critical date under § 102(b). [read post]
